Nurix Therapeutics/NRIX

$11.88

6.54%
-
1D1W1MYTD1YMAX

About Nurix Therapeutics

Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecules and antibody therapies based on the modulation of cellular protein levels as a treatment approach for cancer, inflammatory conditions and other diseases. It DELigase is an integrated discovery platform, to identify and advance drug candidates targeting E3 ligases. Its drug candidates include NX-2127, NX-5948 and NX-1607. NX-2127 is an orally bioavailable Brutons tyrosine kinase (BTK) degrader that also degrades cereblon neosubstrates IKZF1 (Ikaros) and IKZF3 (Aiolos) for the treatment of relapsed or refractory B-cell malignancies. NX-5948 is an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and potentially autoimmune diseases. NX-1607 is an oral clinical-stage small molecule drug candidate that inhibits Casitas B-lineage lymphoma proto-oncogene-B (CBL-B).

Ticker

NRIX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Arthur Sands

Employees

284

Headquarters

San francisco, United States

NRIX Metrics

BasicAdvanced
$498.72M
Market cap
-
P/E ratio
-$2.65
EPS
1.94
Beta
-
Dividend rate

What the Analysts think about NRIX

Analyst Ratings

Majority rating from 11 analysts.
Buy

Price Targets

Average projection from 10 analysts.
96.13% upside
High $35.00
Low $10.00
$11.88
Current price
$23.30
Average price target

NRIX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-277.48% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$15.1M
-17.93%
Net income
$-41.9M
13.55%
Profit margin
-277.48%
38.37%

NRIX Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 35.09%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.75
-$0.45
-$0.68
-$0.77
-
Expected
-$0.87
-$0.56
-$0.76
-$0.57
-$0.80
Surprise
-13.59%
-19.64%
-10.03%
35.09%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Nurix Therapeutics stock

Buy or sell Nurix Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing